Corbus Pharmaceuticals Stock Drops After CRB-701 Trial Update
Corbus drug CRB-701 showed early cancer activity, but mixed results and small trials led stock to drop 26%. Larger study ahead.
/ 2 items
Corbus drug CRB-701 showed early cancer activity, but mixed results and small trials led stock to drop 26%. Larger study ahead.
Corbus Pharmaceuticals gets Buy rating ($45 target). Drug CRB-701 shows strong cancer results, safer than rivals. Stock down 43% may be opportunity.